Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 6/20 | 0.49 |
| ▸ | THRA | P10827 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14024231 | 0.89 | TPMT (0.65) | TPMTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL6135987 | 0.85 | TSHR (0.52) | TPMTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL237992 | 0.85 | CA1 (0.58) | TPMTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL6136142 | 0.82 | POLB (0.44) | TPMTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL6135844 | 0.81 | NPC1 (0.48) | KDM4EALDH1A1LMNAPOLBL3MBTL1 | |
| SCHEMBL6135981 | 0.81 | PCNA (0.56) | TPMTKDM4ELMNAPOLBGAA | |
| SCHEMBL28534372 | 0.79 | TPMT (0.53) | TPMTKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL28651171 | 0.78 | THRB (0.41) | TPMTTHRBTHRAPPARGRXRA | |
| SCHEMBL31573574 | 0.78 | TPMT (0.51) | TPMTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL10322627 | 0.78 | ALDH1A1 (0.51) | TPMTKDM4EALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | claimed |
| US-20100279327-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2010-11-04 | — | — | US | claimed |
| EP-2038654-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | Bipar Sciences, Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008147418-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080262062-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2008-10-23 | — | — | US | claimed |
| US-20070292883-A1 | Method of treating diseases with PARP inhibitors | BIPAR SCIENCES, INC. | 2007-12-20 | — | — | US | claimed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20210393791-A1 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | HEALTH RESEARCH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| EP-3594343-B1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021041532-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2012009475-A1 | METHODS OF TREATING CANCER WITH INHIBITION OF LYSINE-SPECIFIC DEMETHYLASE 1 | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| US-20100279327-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2038654-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | Bipar Sciences, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008147418-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080262062-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | BIPAR SCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070292883-A1 | Method of treating diseases with PARP inhibitors | BIPAR SCIENCES, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262062-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | PARP3, PARP2, PARP4 | TPMT 2012/4885THRB 2238/4885THRA 2348/4885 |
| US-20100279327-A1 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS | PARP3, PARP4, PARP2 | TPMT 1999/4885THRB 2358/4885THRA 2493/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | TPMT 2709/4885THRB 4643/4885THRA 4655/4885 |
| US-20070292883-A1 | Method of treating diseases with PARP inhibitors | PARP3, PARP12, PARP2 | TPMT 2164/4885THRB 2053/4885THRA 2343/4885 |
| US-20210393791-A1 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | PARP3, PARP1, PARP11 | TPMT 2993/4885THRB 4779/4885THRA 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.